Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.gov_Identifier |
NCT00567190
|
| gptkbp:conditionStudied |
HER2-positive metastatic breast cancer
|
| gptkbp:controls |
placebo plus trastuzumab and docetaxel
|
| gptkbp:endPoint |
progression-free survival
|
| gptkbp:enrollment |
808 patients
|
| gptkbp:firstPublished |
2012
|
| gptkbp:fullName |
Clinical Evaluation of Pertuzumab and Trastuzumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
CLEOPATRA trial
|
| gptkbp:intervention |
gptkb:pertuzumab
gptkb:trastuzumab docetaxel |
| gptkbp:location |
international
|
| gptkbp:period |
Phase III
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
improved overall survival with pertuzumab
improved progression-free survival with pertuzumab |
| gptkbp:secondaryEndpoint |
overall survival
|
| gptkbp:sponsor |
gptkb:Genentech
F. Hoffmann-La Roche Ltd. |
| gptkbp:startYear |
2008
|
| gptkbp:bfsParent |
gptkb:HER2-positive_breast_cancer
gptkb:pertuzumab |
| gptkbp:bfsLayer |
7
|